Ceryvyn Therapeutics (ASX:CYV) Days Payable: 0.00 (As of Jun. 2025)


What is Ceryvyn Therapeutics Days Payable?

Ceryvyn Therapeutics ASX:CYV -7.69% Days Payable is 0.00 as of Jun. 2025. The stock has 3 warning signs investors should review. Among 701 Biotechnology companies, Ceryvyn Therapeutics ranks worse than 142653.21% on this metric.

Ceryvyn Therapeutics's average Accounts Payable for the six months ended in Jun. 2025 was A$11.74 Mil. Ceryvyn Therapeutics's Cost of Goods Sold for the six months ended in Jun. 2025 was A$0.00 Mil.

The historical rank and industry rank for Ceryvyn Therapeutics's Days Payable or its related term are showing as below:

During the past 13 years, Ceryvyn Therapeutics's highest Days Payable was 31631.61. The lowest was 2939.84. And the median was 8566.38.

ASX:CYV's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84
* Ranked among companies with meaningful Days Payable only.

Ceryvyn Therapeutics's Days Payable stayed the same from Jun. 2024 (0.00) to Jun. 2025 (0.00).

Ceryvyn Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Days Payable Chart

Ceryvyn Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,939.84 18,921.44 31,631.61 0.00 0.00

Ceryvyn Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28,791.93 0.00 0.00 0.00 0.00

ASX:CYV vs VRTX, REGN, ALNY: Days Payable Comparison

For the Biotechnology subindustry, Ceryvyn Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ceryvyn Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Ceryvyn Therapeutics's Days Payable falls into.


Ceryvyn Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Ceryvyn Therapeutics's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as

Days Payable (A: Jun. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Jun. 2024 ) + Accounts Payable (A: Jun. 2025 )) / count ) / Cost of Goods Sold (A: Jun. 2025 )*Days in Period
=( (57.318 + 14.954) / 2 ) / 0*365
=36.136 / 0*365
=N/A

Ceryvyn Therapeutics's Days Payable for the quarter that ended in Jun. 2025 is calculated as:

Days Payable (Q: Jun. 2025 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2024 ) + Accounts Payable (Q: Jun. 2025 )) / count ) / Cost of Goods Sold (Q: Jun. 2025 )*Days in Period
=( (8.522 + 14.954) / 2 ) / 0*365 / 2
=11.738 / 0*365 / 2
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Ceryvyn Therapeutics (ASX:CYV) has a Days Payable of 0.00 as of Jun. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ceryvyn Therapeutics and its competitors. Over the past decade, Ceryvyn Therapeutics' Days Payable has ranged from 2,939.84 to 31,631.61. According to the industry distribution chart, Ceryvyn Therapeutics ranks #999999 out of 701 companies in the Biotechnology industry.
Is Ceryvyn Therapeutics' Days Payable too high?
Ceryvyn Therapeutics' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 2,939.84 to a high of 31,631.61. Based on the distribution chart, Ceryvyn Therapeutics ranks #999999 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Ceryvyn Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ceryvyn Therapeutics ranks #999999 out of 701 companies for Days Payable. This places Ceryvyn Therapeutics in the lower half of its industry. The industry median Days Payable is 112.84. Historically, Ceryvyn Therapeutics' own Days Payable has ranged from 2,939.84 to 31,631.61 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ceryvyn Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ceryvyn Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current Days Payable of 0.00. The current Days Payable is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current Days Payable is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.